Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study-Reference-Cited by-同舟云学术

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

Published:2022-09 Issue:9 Volume:23 Page:1145-1155
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Dummer Reinhard,Queirolo Paola,Abajo Guijarro Ana Maria,Hu Youyou,Wang Dao,de Azevedo Sergio Jobim,Robert Caroline,Ascierto Paolo Antonio,Chiarion-Sileni Vanna,Pronzato Paolo,Spagnolo Francesco,Mujika Eizmendi Karmele,Liszkay Gabriella,de la Cruz Merino Luis,Tawbi Hussein

Funder

F. Hoffmann-La Roche

Roche

Publisher

Elsevier BV

Subject

Oncology

Reference23 articles.

1. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial;Long;Lancet Oncol,2012

2. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study;Dummer;Eur J Cancer,2014

3. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial;Davies;Lancet Oncol,2017

4. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study;McArthur;Ann Oncol,2017

5. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma;Geukes Foppen;Melanoma Res,2018

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy;International Journal of Nanomedicine;2024-05

2. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey;Melanoma Research;2024-03-28

3. Primary Cutaneous Melanoma—Management in 2024;Journal of Clinical Medicine;2024-03-11

4. Melanoma Brain Metastases: Immunotherapy or Targeted Therapy? A Systematic Review and Meta-Analyses;Applied Sciences;2024-03-07

5. Levothyroxine personalized treatment: is it still a dream?;Frontiers in Endocrinology;2024-01-08